Matinas BioPharma Holdings, Inc. (OTCQB: MTNB), a development stage biopharmaceutical company, focuses on identifying, developing, and commercializing pharmaceutical products for the treatment of dyslipidemia and cardiovascular disease. It primarily focuses on developing MAT9001, a proprietary prescription-grade omega-3 fatty acid composition for the treatment of severe hypertriglyceridemia. SNNLive caught up with Roelof M.L. Rongen, Co-Founder, President and CEO of Matinas BioPharma Holdings, Inc. at the Growth Capital Expo 2015 in Las Vegas, NV.
“Matinas BioPharma is a biopharma company, development-stage company, focused on lipid-based therapies. We focus on cardiovascular metabolic as our therapeutic area of focus, and we recently built out our portfolio in the anti-infective field – very important and exciting field. We have a very unique lipid-delivery technology that we acquired through the acquisition of Aquarius Biotechnologies last January,” Mr. Rongen begins.
He goes on to provide an update on the company. Mr. Rongen closes out the interview discussing what he expects for the rest of 2015, going into 2016. For more information about Matinas BioPharma Holdings, Inc., go to: www.MatinasBioPharma.com
Since speaking with Mr. Rongen, the company has made the following announcements:
© 2017 Stock News Now
Supported by Superior Web Solutions